Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Treasury Shares (2017 - 2024)

Historic Treasury Shares for Arcus Biosciences (RCUS) over the last 8 years, with Q4 2024 value amounting to $2.2 million.

  • Arcus Biosciences' Treasury Shares rose 4666.67% to $2.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.2 million, marking a year-over-year increase of 4666.67%. This contributed to the annual value of $2.2 million for FY2024, which is 4666.67% up from last year.
  • Arcus Biosciences' Treasury Shares amounted to $2.2 million in Q4 2024, which was up 4666.67% from $1.5 million recorded in Q4 2023.
  • In the past 5 years, Arcus Biosciences' Treasury Shares registered a high of $2.2 million during Q4 2024, and its lowest value of $653950.0 during Q3 2020.
  • Moreover, its 5-year median value for Treasury Shares was $1.2 million (2021), whereas its average is $1.2 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first soared by 6228.43% in 2020, then skyrocketed by 1538.46% in 2023.
  • Quarter analysis of 5 years shows Arcus Biosciences' Treasury Shares stood at $738650.0 in 2020, then skyrocketed by 48.92% to $1.1 million in 2021, then grew by 18.18% to $1.3 million in 2022, then grew by 15.38% to $1.5 million in 2023, then soared by 46.67% to $2.2 million in 2024.
  • Its last three reported values are $2.2 million in Q4 2024, $1.5 million for Q4 2023, and $1.3 million during Q4 2022.